Skip to main content
. 2014 Oct;134(4):686–695. doi: 10.1542/peds.2014-0571

TABLE 2.

T-Cell Subsets in Children With Sickle Cell Disease

Entry Age 24 mo Exit
HU Placebo P HU Placebo P HU Placebo P
Number of participants 91 88 74 72 86 86
Lymphocytes/mm3a 6776 (0.67) 7106 (0.67) .494 5218 (0.66) 6550 (0.68) .003 4386 (0.67) 5219 (0.67) .012
CD3 %b 53 (11) 54 (12) .936 56 (10) 51 (11) .016 55 (10) 52 (11) .064
CD3 #a 3527 (0.67) 3739 (0.66) .394 2859 (0.65) 3288 (0.66) .040 2384 (0.67) 2670 (0.67) .096
CD4 %b 36 (10) 36 (10) .856 34 (8) 33 (9) .185 32 (8) 32 (9) .653
CD4 #a 2357 (0.67) 2572 (0.67) .199 1770 (0.65) 2068 (0.66) .022 1365 (0.67) 1584 (0.67) .031
Naive CD4+CD45RA+ %b 77 (9) 78 (8) .482 71 (10) 70 (10) .455 68 (11) 66 (11) .150
Naive CD4+CD45RA+ #a 1795 (0.69) 1986 (0.69) .195 1249 (0.68) 1437 (0.69) .084 916 (0.71) 1022 (0.71) .199
Memory CD4+CD45RO+ %b 17 (8) 16 (7) .595 22 (10) 23 (8) .513 26 (10) 27 (10) .212
Memory CD4+CD45RO+ #a 347 (0.73) 374 (0.75) .422 359 (0.66) 445 (0.67) .003 324 (0.67) 409 (0.66) <.001
CD8 %b 15 (6) 15 (7) .950 18 (7) 16 (7) .112 19 (7) 17 (6) .070
CD8 #a 978 (0.70) 1053 (0.73) .389 882 (0.70) 975 (0.70) .267 782 (0.71) 847 (0.70) .334
Naive CD8+CD45RA+ %b 85 (9) 85 (10) .922 84 (10) 82 (12) .309 85 (7) 82 (9) .026
Naive CD8+CD45RA+ #a 824 (0.70) 884 (0.73) .406 735 (0.69) 792 (0.68) .370 661 (0.71) 691 (0.70) .590
Memory CD8+CD45RO+ %b 9.00 (8) 9.40 (8) .754 9.50 (9) 11 (8) .417 8.80 (6) 11 (6) .031
Memory CD8+CD45RO+ #a 66 (0.99) 76 (0.94) .336 63 (0.99) 82 (0.98) .110 57 (0.86) 78 (0.80) .008

HU, hydroxyurea.

a

Counts are summarized by geometric means (coefficient of variation) and t test to compare log-transformed counts.

b

Percentages are summarized by treatment means (SD) and t test.